B. Riley Securities Maintains Buy on TG Therapeutics, Raises Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Mayank Mamtani maintains a Buy rating on TG Therapeutics (NASDAQ:TGTX) and raises the price target from $24 to $29.
February 05, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B. Riley Securities maintains a Buy rating on TG Therapeutics and raises the price target from $24 to $29.
The upgrade in the price target by B. Riley Securities reflects a positive outlook on TG Therapeutics, likely due to strong company fundamentals or potential market growth. This analyst endorsement can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100